



Viamet Announces Appointment of Amir Tavakkol, Ph.D., as Chief Development Officer

July 22, 2014, Research Triangle Park, North Carolina – [Viamet Pharmaceuticals, Inc.](http://www.viamet.com) today announced the appointment of Amir Tavakkol, Ph.D., as Chief Development Officer. Dr. Tavakkol brings over 25 years of experience in pharmaceuticals, consumer healthcare and academia, including substantial expertise in the clinical development of novel antifungal products for superficial as well as systemic indications. Dr. Tavakkol will have significant responsibility for the management of Viamet's clinical programs, including the ongoing clinical development of VT-1161, the Company's lead novel, oral antifungal compound. The Company plans to begin Phase 2b trials of VT-1161 for recurrent vulvovaginal candidiasis and onychomycosis in the second half of 2014.

Prior to joining Viamet, Dr. Tavakkol most recently served as Senior Vice President of Clinical Development & Operations at Topica Pharmaceuticals Inc., a privately-held, clinical-stage pharmaceutical company. Dr. Tavakkol was previously Project Leader at Merck & Co., a pharmaceutical company. Prior to Merck, Dr. Tavakkol served as Senior Director – Dermatology Clinical Research at Schering Plough. In addition, Dr. Tavakkol was previously with Novartis, where he served as Director of Dermatology Clinical Research. Dr. Tavakkol has conducted clinical research and published on a range of fungal infections, including onychomycosis, and on the treatment of fungal diseases with drugs such as Lamisil® and Noxafil®. Dr. Tavakkol received a Ph.D. in Bacteriology & Virology and a Postgraduate Diploma in Infectious Disease, both from The University of Manchester, UK.

About Viamet (www.viamet.com)

Viamet is a biopharmaceutical company focused on the discovery, development and commercialization of novel antifungal agents based on a proprietary metalloenzyme medicinal chemistry platform, the Metallophile® Technology. The Company is using this platform to design drugs that are expected to have greater selectivity, fewer side effects and improved potency compared to currently available antifungal agents. The Company's lead product candidate, VT-1161, is an oral agent that is being developed for the treatment of recurrent vulvovaginal candidiasis, or RVVC, a highly prevalent mucosal infection for which there are no approved therapies in the United States, and onychomycosis, a very common fungal infection of the nail for which current treatments are suboptimal with respect to safety, tolerability and efficacy. The Company's pipeline also includes preclinical programs that the Company is developing to treat life-threatening invasive fungal infections.

Contact:

Rich Katz, M.D., Chief Business and Financial Officer
Viamet Pharmaceuticals, Inc.
4505 Emperor Boulevard, Suite 300
Durham, North Carolina, USA 27703
Telephone: +919.467.8539 ext. 316

This press release includes forward-looking statements. Actual results may vary materially from these statements. There are many important risks affecting Viamet's business and VT-1161, including that clinical trials may not be commenced, and if commenced, may not be successful, regulatory approvals may not be obtained and approved products, if any, may not achieve commercial success.

The Viamet group of companies includes Viamet Pharmaceuticals Holdings, LLC and its operating subsidiaries, Viamet Pharmaceuticals, Inc., VPS-1, Inc., VPS-2, Inc. and VPS-3, Inc. The Viamet group of companies is based in the Research Triangle Park region of North Carolina, USA.